Archives

  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • Atrial Natriuretic Peptide (ANP), rat: Mechanistic and Be...

    2026-03-12

    Atrial Natriuretic Peptide (ANP), rat: Mechanistic and Benchmark Review for Cardiovascular Research

    Executive Summary: Atrial Natriuretic Peptide (ANP), rat is a 28-amino acid peptide hormone with a molecular formula of C49H84N20O15S and a molecular weight of 1225.38 g/mol, synthesized and secreted by atrial myocytes in the heart in response to atrial distension and neurohumoral stimuli [APExBIO]. ANP acts as a potent vasodilator and natriuretic agent, directly lowering blood pressure by promoting sodium and water excretion [Zhang et al., 2022]. The product, supplied by APExBIO, is characterized by ≥95.92% purity (HPLC/MS), is soluble at ≥122.5 mg/mL in DMSO and ≥43.5 mg/mL in water, and is widely used in cardiovascular and renal physiology research [APExBIO]. ANP’s mechanism involves cyclic GMP-mediated vasorelaxation and the modulation of renal sodium handling. Recent research highlights its emerging roles in adipose tissue metabolism and neuroimmune signaling [Perspective].

    Biological Rationale

    Atrial Natriuretic Peptide (ANP) is a key regulator of cardiovascular homeostasis in mammals. It is produced, stored, and secreted by atrial myocytes in response to increased atrial pressure, volume expansion, angiotensin II, endothelin, and sympathetic activation [APExBIO]. ANP exerts its primary effect by stimulating guanylyl cyclase-linked natriuretic peptide receptors (NPR-A), resulting in increased intracellular cyclic GMP (cGMP) levels and subsequent smooth muscle relaxation. This leads to vasodilation and increased glomerular filtration, promoting natriuresis and diuresis [Zhang et al., 2022]. The peptide’s influence extends to modulation of adipose tissue metabolism and neuroinflammatory pathways, positioning it as a multifaceted probe in both cardiovascular and metabolic research [Molecular Insights]. This article extends prior molecular discussions by systematically benchmarking ANP’s experimental characteristics across physiological systems.

    Mechanism of Action of Atrial Natriuretic Peptide (ANP), rat

    ANP’s primary mechanism involves binding to natriuretic peptide receptor-A (NPR-A) on target cells, activating membrane-bound guanylyl cyclase, and increasing intracellular cGMP. Elevated cGMP induces relaxation of vascular smooth muscle cells, resulting in potent vasodilation and reduced systemic vascular resistance [APExBIO]. In the kidney, ANP increases glomerular filtration rate (GFR) and inhibits sodium reabsorption in the distal nephron, leading to natriuresis and diuresis. ANP also counteracts the renin-angiotensin-aldosterone system (RAAS) by inhibiting renin and aldosterone secretion. In adipose tissue, ANP promotes lipolysis via cGMP-dependent protein kinase (PKG) signaling pathways [Systems Biology]. Recent systems biology approaches reveal cross-system signaling, including indirect modulation of neuroimmune pathways in the context of cardiovascular disease and metabolic syndrome.

    Evidence & Benchmarks

    • ANP, rat (SKU: A1009, APExBIO) is supplied as a solid powder at ≥95.92% purity (HPLC/MS), ensuring high experimental reproducibility in mechanistic and translational studies (APExBIO product page).
    • ANP’s vasodilatory effect is mediated via cGMP production in vascular smooth muscle cells; this pathway directly lowers blood pressure in rat models (Zhang et al., 2022).
    • Solubility is ≥122.5 mg/mL in DMSO and ≥43.5 mg/mL in water at room temperature; ANP is insoluble in ethanol (APExBIO).
    • Storage at -20°C is required to maintain peptide stability; reconstituted solutions should be used promptly and not stored long-term (APExBIO).
    • In vivo and ex vivo studies show ANP enhances natriuresis and diuresis, suppresses aldosterone/renin release, and modulates adipose tissue metabolism (Mechanisms, Models).
    • ANP’s role in neuroimmune crosstalk is emerging, with evidence for indirect modulation of inflammatory and oxidative stress pathways in rodent models (Zhang et al., 2022).

    This article updates the systems biology perspective by providing experimental benchmarks and clarifying solubility, purity, and functional endpoints versus prior overviews [Systems Biology].

    Applications, Limits & Misconceptions

    Major Research Applications:

    • Blood pressure regulation studies (vasodilation, baroreflex).
    • Natriuresis mechanism and renal physiology research.
    • Adipose tissue metabolism and lipolysis modulation.
    • Translational models of cardiovascular and renal disease.
    • Cross-talk studies in neuroimmune and metabolic signaling.

    For advanced experimental strategies, see Translating Mechanistic Insights. This review clarifies mechanistic endpoints and quality controls not detailed in that article.

    Common Pitfalls or Misconceptions

    • ANP is not effective for chronic hypertension of non-cardiac origin (e.g., monogenic forms or renovascular hypertension).
    • The peptide’s vasodilatory effects are short-lived due to rapid enzymatic degradation in vivo.
    • ANP does not directly modulate neuroinflammation; its effects are peripheral and mediated via cardiovascular or metabolic changes.
    • Incorrect solvent use (e.g., ethanol) leads to insolubility and experimental failure.
    • Extended storage of reconstituted ANP solutions degrades peptide integrity and activity.

    Workflow Integration & Parameters

    ANP, rat (APExBIO, A1009) is supplied as a lyophilized solid at ≥95.92% purity. Reconstitute in DMSO (≥122.5 mg/mL) or water (≥43.5 mg/mL) at room temperature. Do not use ethanol as a solvent. Store lyophilized material at -20°C; use freshly prepared solutions for each experimental session. ANP is suitable for in vitro, ex vivo, and in vivo studies in cardiovascular, renal, and metabolic research. For mechanistic probing, use concentrations based on reported EC50 values (typically 10-8 to 10-6 M for vascular smooth muscle relaxation). Follow established protocols for blood pressure, natriuresis, or lipolysis assays. The product is highly compatible with rodent models, aligning with published benchmarks and enabling reproducible phenotype modulation [Mechanisms, Models].

    Conclusion & Outlook

    Atrial Natriuretic Peptide (ANP), rat from APExBIO (A1009) is a validated, high-purity peptide for dissecting cardiovascular, renal, and metabolic mechanisms in preclinical research. Its precise molecular action, robust solubility, and reproducible effects make it a standard for blood pressure homeostasis and natriuresis studies. ANP’s translational potential in neuroimmune modulation is an emerging area, warranting further mechanistic exploration. By integrating this peptide into workflow, researchers can benchmark and extend foundational studies in cardiovascular disease and metabolic regulation. For detailed insights and advanced protocols, visit the Atrial Natriuretic Peptide (ANP), rat product page or consult recent mechanistic reviews [Molecular Insights], noting this article benchmarks purity and solubility parameters not addressed previously.